Valneva SE (LON:0OB3)
2.408
-0.029 (-1.20%)
At close: Jul 7, 2025
Valneva SE Revenue
Valneva SE had revenue of 49.23M EUR in the quarter ending March 31, 2025, with 50.31% growth. This brings the company's revenue in the last twelve months to 186.06M, up 21.64% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
186.06M EUR
Revenue Growth
+21.64%
P/S Ratio
2.40
Revenue / Employee
260.95K EUR
Employees
713
Market Cap
373.69M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Indivior | 905.57M |
Valneva SE News
- 15 days ago - Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus - GlobeNewsWire
- 15 days ago - Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance - GlobeNewsWire
- 4 weeks ago - UK's MHRA suspends Valneva's chikungunya vaccine for elderly - Reuters
- 5 weeks ago - Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026 - Benzinga
- 5 weeks ago - Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 5 weeks ago - Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Valneva to Participate at U.S. and European Investor Conferences in June - GlobeNewsWire
- 2 months ago - Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States - GlobeNewsWire